Cargando…
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
BACKGROUND: For patients with metastatic renal cell carcinoma (mRCC), targeted therapies have entered the market since 2006. The aims of this study were to evaluate the uptake and use of targeted therapies for mRCC in The Netherlands, examine factors associated with the prescription of targeted ther...
Autores principales: | De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B. A. G., Kiemeney, L. A. L. M., Uyl-de Groot, C. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902930/ https://www.ncbi.nlm.nih.gov/pubmed/27286871 http://dx.doi.org/10.1186/s12885-016-2395-x |
Ejemplares similares
-
Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
por: de Groot, S., et al.
Publicado: (2017) -
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017) -
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022) -
Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018) -
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)